Four-Week Neoadjuvant 5% Imiquimod Before Mohs Micrographic Surgery for Melanoma In Situ: A Prospective Pilot Study

Figure legend:

Supplementary Figure 1: Detailed methods section. Expanded description of the methods employed in this investigation.

Supplementary Figure 2A-B: Photos of histopathology of representative complete responder. (2A) Original biopsy from the left medial buccal cheek showing MIS characterized by asymmetric lentiginous junctional melanocytic proliferation of single and nests of melanocytes on sun-damaged skin. (2B) Mohs layer with MART-1 stain after 4 weeks of imiquimod treatment. Black arrows show normal melanocyte spacing along dermal-epidermal junction.

Supplementary Figure 3: Active tumor debulking using topical imiquimod. Lesion and surrounding skin reacting to a course of topical imiquimod.

Supplementary Table 1: Combined table showing patient demographics and clinical tumor response to imiquimod. Displayed data includes age/sex; tumor location; prior history of skin cancer; family history, past medical history; original tumor area (cm2), post-neoadjuvant tumor area (cm2); and tumor percent change in area.

图注：
补充图1：详细方法章节。本研究采用的实验方法的扩展说明。
补充图2A-B：典型完全应答者的组织病理学(histopathology)图像。(2A) 左侧内侧颊黏膜的初始活检样本，显示原位黑素瘤(Melanoma In Situ, MIS)，特征为日光损伤皮肤上的单个黑素细胞及黑素细胞巢呈不对称性雀斑样交界性黑素细胞增生。(2B) 经咪喹莫特(imiquimod)治疗4周后的莫氏(Mohs)切片层行MART-1染色(MART-1 stain)，黑色箭头标示真皮-表皮交界处正常黑素细胞的分布间距。
补充图3：外用咪喹莫特(imiquimod)主动肿瘤减瘤。病灶及周围皮肤对一个疗程的外用咪喹莫特产生应答反应。
补充表1：整合患者人口统计学特征与临床肿瘤对咪喹莫特应答情况的汇总表格。所展示的数据包括：年龄/性别、肿瘤部位、既往皮肤癌病史、家族病史、既往病史、初始肿瘤面积(cm²)、新辅助治疗后肿瘤面积(cm²)以及肿瘤面积变化百分比。